Dan Wei

Mrs. Dan Wei

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2020 in Life Sciences
Verified
Journal Article
Closed access
DWDan Wei
Dan Wei
LLLin Liao
Lin Liao
HWHuanjun Wang
Huanjun Wang
WZWei Zhang
Wei Zhang
TWTingting Wang
Tingting Wang
ZXZhipeng Xu
Zhipeng Xu

1 January 2022 in Yonsei Medical Journal
Verified
Journal Article
Open access
PDF file
ZXZhipeng Xu
Zhipeng Xu
WHWenxin Hu
Wenxin Hu
BWBin Wang
Bin Wang
TXTing Xu
Ting Xu
JWJianning Wang
Jianning Wang
DWDan Wei
Dan Wei
Xu Z, et al. Yonsei Med J. 2022 Jul;63(7):619-631. https://doi.org/10.3349/ymj.2022.63.7.619

22 March 2022 in Cell Death Discovery
Verified
Journal Article
Open access
PDF file
ZXZhipeng Xu
Zhipeng Xu
MLMin Liu
Min Liu
JWJin Wang
Jin Wang
KLKai Liu
Kai Liu
LXLiuyu Xu
Liuyu Xu
JWJianning Wang
Jianning Wang
Clear cell renal cell carcinoma (ccRCC) is a serious threat to human health worldwide, while its heterogeneity limits therapeutic success and leads to poor survival outcomes. Single-cell RNA-sequencing (scRNA-seq) is an important technology, which provides deep insights into the genetic characteristics of carcinoma. In this study, we profiled the gene expression of single cells from human ccRCC tissues and adjacent normal tissues using the scRNA-seq. We found that MYH9 was commonly upregulated in the ccRCC cell subgroup. Additionally, MYH9 was of highly expression in ccRCC tissues and predicted poor prognosis of ccRCC patients. MYH9 knockdown in ccRCC cells dampened their proliferative and metastatic potentials, whereas MYH9 overexpression enhanced these properties. In vivo, MYH9 also promoted ccRCC growth. Mechanistic studies showed that MYH9 played these vital roles through AKT signaling pathway. Furthermore, MYH9/AKT axis determined the responses of ccRCC cells to sunitinib treatment and might serve as a biomarker for sunitinib benefits in ccRCC patients. Thus, MYH9 might be a novel therapeutic target and prognostic predictor for ccRCC.

1 August 2021 in Canadian Journal of Physiology and Pharmacology
Verified
Journal Article
Closed access
DWDan Wei
Dan Wei
SWShaofei Wu
Shaofei Wu
JLJie Liu
Jie Liu
XZXiaoqian Zhang
Xiaoqian Zhang
XGXiaoling Guan
Xiaoling Guan
ZXZhipeng Xu
Zhipeng Xu
Theobromine, a methylxanthine present in cocoa, has been shown to possess many beneficial pharmacological properties such as anti-oxidative stress, anti-inflammatory property, and anti-microbial activity. In this study, we investigated the effects of theobromine on nonalcoholic fatty liver disease (NAFLD) and the possible underlying mechanisms in vivo and in vitro. The results showed that theobromine reduced body weight and fat mass and improved dyslipidemia. Theobromine mitigated liver injury and significantly reduced hepatic triglyceride level in mice with obesity. Histological examinations also showed hepatic steatosis was alleviated after theobromine treatment. Furthermore, theobromine reversed the elevated mRNA and protein expression of SREBP-1c, FASN, CD36, FABP4, and the suppressed expression of PPARα and CPT1a in the liver of mice with obesity, which were responsible for lipogenesis, fatty acid uptake, and fatty acid oxidation respectively. In vitro, theobromine also downregulated SREBP-1c, FASN, CD36, FABP4 and upregulated PPARα and CPT1a mRNA and protein levels in hepatocytes in a dose-dependent manner, while these changes were reversed by L-leucine, a mammalian target of rapamycin (mTOR) agonist. The present study demonstrated that theobromine improved NAFLD by inhibiting lipogenesis and fatty acid uptake and promoting fatty acid oxidation in the liver and hepatocytes, which might be associated with its suppression of mTOR signaling pathway. Novelty: Theobromine protects against high-fat diet – induced NAFLD. Theobromine inhibits lipogenesis and fatty acid uptake and promotes fatty acid oxidation in the liver and hepatocytes via inhibiting mTOR signaling pathway.

21 April 2021 in Frontiers in Bioengineering and Biotechnology
Verified
Journal Article
Open access
PDF file
MLMi Liu
Mi Liu
DWDan Wei
Dan Wei
ZWZexing Wen
Zexing Wen
JWJian-Bo Wang
Jian-Bo Wang
The creation of C–C bonds is an effective strategy for constructing complex compounds from simple synthetic blocks. Although many methods have been developed for C–C bond construction, the stereoselective creation of new C–C bonds remains a challenge. The selectivities (enantioselectivity, regioselectivity, and chemoselectivity) of biocatalysts are higher than those of chemical catalysts, therefore biocatalysts are excellent candidates for use in stereoselective C–C bond formation. Here, we summarize progress made in the past 10 years in stereoselective C–C bond formation enabled by two classic types of enzyme, aldolases and hydroxynitrile lyases. The information in this review will enable the development of new routes to the stereoselective construction of C–C bonds.

29 August 2024 in Journal of Cancer Research and Therapeutics
Verified
Journal Article
Open access
YHYajie Hu
Yajie Hu
ZXZhipeng Xu
Zhipeng Xu
DZDongsheng Zhou
Dongsheng Zhou
HHHaitao Hou
Haitao Hou
BLBin Liu
Bin Liu
QZQuanlin Zhao
Quanlin Zhao
Aims: Papillary thyroid cancer (PTC) is a serious threat to human health worldwide, while metastasis in the early phase limits therapeutic success and leads to poor survival outcomes. The CXC chemokine receptor type 4 (CXCR4) plays an important role in many cellular movements such as transcriptional modulation, cell skeleton rearrangement, and cell migration, and the change in CXCR4 levels are crucial in various diseases including cancer. In this study, we explored the role of CXCR4 in the migration and invasion of PTC and investigated the potential mechanisms underlying its effects. Subjects and Methods: We analyzed the expression levels of CXCR4 in PTC tissues and cell lines. Would healing migration, Transwell invasion assay in vitro, and tail-vein lung metastasis assay In vivo were performed to evaluated the migration and invasion abilities of PTC cells with stable CXCR4 knockdown or overexpression. Signal transducers and activators of transcription (STAT3) signaling pathway-related protein expressions were examined by Western blotting assays. Results: The results showed that CXCR4 was highly expressed in PTC cell lines and PTC tissues. CXCR4 knockdown in PTC cells dampened the migration, invasion, and epithelial–mesenchymal transition (EMT), whereas CXCR4 overexpression enhanced these properties. In vivo, we also found that CXCR4 promoted the metastasis of PTC. Mechanistic studies showed that CXCR4 played these vital roles through the STAT3 signaling pathway. Furthermore, PTC patients with high CXCR4 or p-STAT3 expression correlated with aggressive clinical characteristics such as extrathyroidal extension (ETE), and lymph node metastasis (LNM). Conclusions: We provided evidence that CXCR4 might activate the STAT3 signaling pathway and further promote PTC development. Thus, CXCR4 might be a novel therapeutic target for PTC.